Microglial priming by IFN-γ involves STAT1-mediated activation of the NLRP3 inflammasome

Haili He1, Xiaomei Zhang2, Hui He2

  • 1Resource Institute for Chinese and Ethnic Materia Medica, Guizhou University of Traditional Chinese Medicine, Guiyang, China.

PubMed
Abstract

Insights

Interferon (IFN)-γ primes brain microglia via STAT1 activation, leading to NLRP3 inflammasome activation and associated behavioral changes. Inhibiting this IFN-γ/STAT1 pathway may offer therapeutic potential for neurodegenerative and psychiatric disorders.

Area of Science:

  • Neuroscience
  • Immunology
  • Molecular Biology

Background:

  • Neuroinflammation, particularly microglial priming, is implicated in neuropsychiatric disorders.
  • Interferon (IFN)-γ is a known inducer of microglial priming, but the underlying mechanisms remain poorly understood.

Purpose of the Study:

  • To elucidate the mechanism by which IFN-γ induces microglial priming.
  • To investigate the role of the NLRP3 inflammasome in IFN-γ-mediated microglial activation.
  • To assess the behavioral consequences of IFN-γ-induced microglial priming in vivo.

Main Methods:

  • Primary microglia and mouse brains were used to examine the effects of IFN-γ on gene expression, microglial activation, and inflammasome activity.
  • STAT1 inhibition was employed using fludarabin to investigate its role in IFN-γ signaling.
  • Behavioral tests were conducted in mice following IFN-γ administration.

Main Results:

  • IFN-γ treatment induced microglial activation, pro-inflammatory responses, and NLRP3 inflammasome activation, while suppressing homeostatic markers.
  • IFN-γ-primed microglia exhibited heightened responses to lipopolysaccharide (LPS) stimulation.
  • In vivo administration of IFN-γ led to anxiety- and depression-like behaviors and impaired spatial memory, which were mitigated by STAT1 inhibition.

Conclusions:

  • IFN-γ primes microglia through STAT1 activation, upregulating NLRP3 inflammasome components.
  • The IFN-γ/STAT1 axis represents a potential therapeutic target for neurodegenerative and psychiatric disorders characterized by microglial priming.